These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 17707641)
1. Angiogenesis as targeted breast cancer therapy. Hayes DF; Miller K; Sledge G Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641 [TBL] [Abstract][Full Text] [Related]
2. The role of angiogenesis inhibition in the treatment of breast cancer. Sledge GW; Rugo HS; Burstein HJ Clin Adv Hematol Oncol; 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. PubMed ID: 17139244 [TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy for breast cancer. Nielsen DL; Andersson M; Andersen JL; Kamby C Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536 [TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and bevacitumab in breast cancer. Bando H Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901 [TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Grothey A; Ellis LM Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in the treatment of breast cancer. Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567 [TBL] [Abstract][Full Text] [Related]
12. The role of antiangiogenesis therapy: bevacizumab and beyond. Cortés-Funes H Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449 [TBL] [Abstract][Full Text] [Related]
13. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017 [TBL] [Abstract][Full Text] [Related]
14. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Marty M; Pivot X Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037 [TBL] [Abstract][Full Text] [Related]
20. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]